I have read the journal's policy and have the following conflicts: RLG is a co-founder of and has an equity ownership interest in VitriVax. There are no proceeds or income to report. RBSR disclosures: Under a licensing agreement between Sanofi-Aventis and the Johns Hopkins University, RBSR is entitled to a share of royalty received by the university on sales of products. The value of these products could be impacted by the outcome of the study described in this article. Under a licensing agreement between PaxVax, the NIH, and the Johns Hopkins University, RBSR is entitled to a share of royalty received by the university on sales of the vaccine described in this article. RBSR is a co-founder of and has an equity ownership interest in Papivax LLC. Also, he owns Papivax Biotech, Inc. stock options and is a member of Papivax Biotech, Inc.'s Scientific Advisory Board. Under a licensing agreement between Papivax Biotech, Inc. and the Johns Hopkins University, the university is entitled to royalties on an invention described in this article. Under an option agreement between PathoVax LLC, the Johns Hopkins University, and University of Vienna Medical School, RBSR is entitled to distributions of payments associated with an invention described in this publication. RBSR also owns equity in PathoVax LLC and is a member of its scientific advisory board. These arrangements have been reviewed and approved by the Johns Hopkins University in accordance with its conflict of interest policies.